Swiss National Bank Cue Biopharma, Inc. Transaction History

Swiss National Bank

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$2.49 - $5.92 $168,324 - $400,192	-67,600 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$4.41 - $12.28 $22,491 - $62,628	5,100 Added 8.16%	67,600 $330,000
Q3 2021 Nov 08, 2021	BUY	$10.06 - $15.3 $21,126 - $32,130	2,100 Added 3.48%	62,500 $911,000
Q2 2021 Aug 06, 2021	BUY	$10.9 - $14.53 $54,500 - $72,650	5,000 Added 9.03%	60,400 $704,000
Q1 2021 May 07, 2021	BUY	$11.2 - $16.09 $22,400 - $32,180	2,000 Added 3.75%	55,400 $676,000
Q4 2020 Feb 05, 2021	BUY	$11.12 - $16.4 $20,016 - $29,519	1,800 Added 3.49%	53,400 $668,000
Q3 2020 Nov 09, 2020	BUY	$15.05 - $23.54 $63,210 - $98,868	4,200 Added 8.86%	51,600 $777,000
Q2 2020 Aug 05, 2020	BUY	$12.7 - $30.73 $601,980 - $1.46 Million	47,400 New	47,400 $1.16 Million

14.1M

14.4K

2.6K

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $49.5M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.